Table of Contents
New Journal of Science
Volume 2014, Article ID 180203, 9 pages
http://dx.doi.org/10.1155/2014/180203
Review Article

The Unravelled Link between Chronic Kidney Disease and Hepatitis C Infection

1Division of Nephrology, Maggiore Hospital and IRCCS Foundation, 20122 Milan, Italy
2Division of Hepatology, School of Medicine, Miami, FL, USA

Received 19 March 2014; Accepted 4 June 2014; Published 3 July 2014

Academic Editor: Alessandro Granito

Copyright © 2014 Fabrizio Fabrizi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. G. Couser, G. Remuzzi, S. Mendis, and M. Tonelli, “The contribution of chronic kidney disease to the global burden of major noncommunicable diseases,” Kidney International, vol. 80, no. 12, pp. 1258–1270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. Q. Zhang and D. Rothenbacher, “Prevalence of chronic kidney disease in population-based studies: systematic review,” BMC Public Health, vol. 8, article 117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. “2008–2013 action plan for the global strategy for the prevention and control of non-communicable diseases: prevent and control of cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes,” World Health Organization.
  4. P. W. Eggers, “Has the incidence of end-stage renal disease in the USA and other countries stabilized?” Current Opinion in Nephrology and Hypertension, vol. 20, no. 3, pp. 241–245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Eckardt, J. Coresh, O. Devuyst et al., “Evolving importance of kidney disease: from subspecialty to global health burden,” The Lancet, vol. 382, no. 9887, pp. 158–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Perico, D. Cattaneo, B. Bikbov, and G. Remuzzi, “Hepatitis C infection and chronic renal diseases,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 207–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Pol, A. Vallet-Pichard, M. Corouge, and V. O. Mallet, “Hepatitis C: epidemiology, diagnosis, natural history and therapy,” Contributions to Nephrology, vol. 176, pp. 1–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. National Kidney Foundation, “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, supplement 1, pp. S1–S266, 2002. View at Google Scholar
  9. J. I. Tsui, E. Vittinghoff, M. G. Shlipak et al., “Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease,” Archives of Internal Medicine, vol. 167, no. 12, pp. 1271–1276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Moe, A. J. Pampalone, S. Ofner, M. Rosenman, E. Teal, and S. L. Hui, “Association of hepatitis C virus infection with prevalence and development of kidney disease,” The American Journal of Kidney Diseases, vol. 51, no. 6, pp. 885–892, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. K. Asrani, P. Buchanan, B. Pinsky, L. R. Rey, M. Schnitzler, and F. Kanwal, “Lack of association between hepatitis C infection and chronic kidney disease,” Clinical Gastroenterology and Hepatology, vol. 8, no. 1, pp. 79–84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. A. Butt, X. Wang, and L. F. Fried, “HCV infection and the incidence of CKD,” American Journal of Kidney Diseases, vol. 57, no. 3, pp. 396–402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. Centers for Disease Control and Prevention (CDC), “Prevalence of chronic kidney disease and associated risk factors- United States, 1999–2004,” Morbidity and Mortality Weekly Report (MMWR), vol. 56, pp. 161–165, 2007. View at Google Scholar
  14. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Klahr, “The kidney in hypertension—villain and victim,” The New England Journal of Medicine, vol. 320, no. 11, pp. 731–733, 1989. View at Publisher · View at Google Scholar · View at Scopus
  16. C. A. Herzog, R. W. Asinger, A. K. Berger et al., “Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO),” Kidney International, vol. 80, no. 6, pp. 572–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. H. Parving, E. Hommel, E. Mathiesen et al., “Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes,” British Medical Journal, vol. 296, no. 6616, pp. 156–160, 1988. View at Publisher · View at Google Scholar · View at Scopus
  18. P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, “Global burden of hypertension: analysis of worldwide data,” The Lancet, vol. 365, no. 9455, pp. 217–223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. W. M. McClellan, R. D. Langston, and R. Presley, “Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease,” Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1912–1919, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Betriu, M. Martinez-Alonso, M. Arcidiacono et al., “Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study,” Nephrology, Dialysis, Transplantation, vol. 29, no. 7, pp. 1415–1422, 2014. View at Publisher · View at Google Scholar
  21. G. Remuzzi, P. Ruggenenti, and N. Perico, “Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition,” Annals of Internal Medicine, vol. 136, no. 8, pp. 604–615, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. M. T. James, B. R. Hemmelgarn, and M. Tonelli, “Early recognition and prevention of chronic kidney disease,” The Lancet, vol. 375, no. 9722, pp. 1296–1309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Fabrizi, P. Colucci, C. Ponticelli, and F. Locatelli, “Kidney and liver involvement in cryoglobulinemia,” Seminars in Nephrology, vol. 22, no. 4, pp. 309–318, 2002. View at Google Scholar · View at Scopus
  24. F. Fabrizi, E. Plaisier, D. Saadoun, P. Martin, P. Messa, and P. Cacoub, “Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease,” The American Journal of Kidney Diseases, vol. 61, no. 4, pp. 623–637, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Fabrizi, G. B. Fogazzi, D. Cresseri et al., “Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature,” Kidney and Blood Pressure Research, vol. 35, no. 6, pp. 687–693, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Cruzado, M. Carrera, J. Torras, and J. M. Grinyó, “Hepatitis C virus infection and de novo glomerular lesions in renal allografts,” American Journal of Transplantation, vol. 1, no. 2, pp. 171–178, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. F. Donato, G. Banfi, D. Cresseri et al., “Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review,” The International Journal of Artificial Organs, vol. 36, no. 5, pp. 367–372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. F. Donato, F. Fabrizi, G. B. Fogazzi et al., “Remission of HCV-associated glomerulonephritis with pegylated IFN and ribavirin therapy after liver transplantation: case report and literature review,” International Journal of Artificial Organs, vol. 36, no. 1, pp. 63–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. KDIGO, “KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease,” Kidney International, vol. 73, no. 109, supplement, pp. S1–S99, 2008. View at Google Scholar
  30. K. Kasuno, T. Ono, A. Matsumori et al., “Hepatitis C virus-associated tubulointerstitial injury,” American Journal of Kidney Diseases, vol. 41, no. 4, pp. 767–775, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Arase, K. Ikeda, N. Murashima et al., “Glomerulonephritis in autopsy cases with hepatitis C virus infection,” Internal Medicine, vol. 37, no. 10, pp. 836–840, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Fabrizi, C. Pozzi, M. Farina et al., “Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal,” Nephrology Dialysis Transplantation, vol. 13, no. 8, pp. 1991–1997, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. H. B. El-Serag, H. Hampel, C. Yeh, and L. Rabeneck, “Extrahepatic manifestations of hepatitis C among United States male veterans,” Hepatology, vol. 36, no. 6, pp. 1439–1445, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Fabrizi, P. Martin, V. Dixit, and P. Messa, “Hepatitis C virus infection and kidney disease: a meta-analysis,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 4, pp. 549–557, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Casato, B. Lagana, L. P. Pucillo, and I. Quinti, “Interferon for hepatitis C virus-negative type II mixed cryoglobulinemia,” The New England Journal of Medicine, vol. 338, no. 19, pp. 1386–1387, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Sansonno, G. Lauletta, M. Montrone, G. Grandaliano, F. P. Schena, and F. Dammacco, “Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection,” Clinical and Experimental Immunology, vol. 140, no. 3, pp. 498–506, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. R. S. Barsoum, “Hepatitis C virus: from entry to renal injury—facts and potentials,” Nephrology Dialysis Transplantation, vol. 22, no. 7, pp. 1840–1848, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Rodríguez-Iñigo, M. Casqueiro, J. Bartolomé et al., “Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases,” Journal of Viral Hepatitis, vol. 7, no. 1, pp. 23–29, 2000. View at Google Scholar · View at Scopus
  39. D. Sansonno, L. Gesualdo, C. Manno, F. P. Schena, and F. Dammacco, “Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis,” Hepatology, vol. 25, no. 5, pp. 1237–1244, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. C. E. Alpers and J. Kowalewska, “Emerging paradigms in the renal pathology of viral diseases,” Clinical Journal of the American Society of Nephrology, vol. 2, supplement 1, pp. S6–S12, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. G. D'Amico, “Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis,” Kidney International, vol. 54, no. 2, pp. 650–671, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. G. D'Amico and A. Fornasieri, “Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus,” American Journal of Kidney Diseases, vol. 25, no. 3, pp. 361–369, 1995. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Wörnle, H. Schmid, B. Banas et al., “Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis,” The American Journal of Pathology, vol. 168, no. 2, pp. 370–385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. Abou-Zeid and H. K. El-Sayegh, “Toll-like receptor 3 gene expression in Egyptian patients with glomerulonephritis and hepatitis C virus infection,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 71, no. 6, pp. 456–461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Kawaguchi, T. Yoshida, M. Harada et al., “Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3,” American Journal of Pathology, vol. 165, no. 5, pp. 1499–1508, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Shintani, H. Fujie, H. Miyoshi et al., “Hepatitis C virus infection and diabetes. Direct involvement of the virus in the development of insulin resistance,” Gastroenterology, vol. 126, no. 3, pp. 840–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Su, C. Su, S. Chang et al., “Association of hepatitis c virus infection with risk of ESRD: a population-based study,” The American Journal of Kidney Diseases, vol. 60, no. 4, pp. 553–560, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. J. N. Hofmann, A. Törner, W. Chow, W. Ye, M. P. Purdue, and A. Duberg, “Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden,” European Journal of Cancer Prevention, vol. 20, no. 4, pp. 326–330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. C. Chen, H. Y. Lin, C. Y. Li, M. S. Lee, and Y. C. Su, “A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease,” Kidney International, vol. 85, no. 5, pp. 1200–1207, 2014. View at Publisher · View at Google Scholar
  50. J. Lee, M. Lin, Y. Yang, S. Lu, H. Chen, and S. Hwang, “Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study,” American Journal of Kidney Diseases, vol. 56, no. 1, pp. 23–31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. L. S. Dalrymple, T. Koepsell, J. Sampson et al., “Hepatitis C virus infection and the prevalence of renal insufficiency,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 4, pp. 715–721, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Lin, Y. Chiu, C. Lee et al., “Factors associated with chronic kidney disease in the elderly and nonelderly population,” Clinical Journal of the American Society of Nephrology, vol. 8, pp. 33–40, 2013. View at Google Scholar
  53. J. Soma, T. Saito, Y. Taguma et al., “High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy,” Journal of the American Society of Nephrology, vol. 11, no. 4, pp. 690–699, 2000. View at Google Scholar · View at Scopus
  54. A. Mocroft, J. Neuhaus, L. Peters et al., “Hepatitis B and C co-infection are independent predictors of progressive kidney disease in hiv-positive, antiretroviral-treated adults,” PLoS ONE, vol. 7, no. 7, Article ID e40245, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Arase, F. Suzuki, Y. Kawamura et al., “Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy,” Hepatology Research, vol. 41, no. 10, pp. 946–954, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Fabrizi, V. Dixit, and P. Messa, “Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?” Journal of Viral Hepatitis, vol. 19, no. 9, pp. 601–607, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Yelken, N. Gorgulu, Y. Caliskan et al., “Association between chronic hepatitis C infection and coronary flow reserve in dialysis patients with failed renal allografts,” Transplantation Proceedings, vol. 41, no. 5, pp. 1519–1523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Oyake, T. Shimada, Y. Murakami et al., “Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients,” Journal of Nephrology, vol. 21, no. 3, pp. 345–353, 2008. View at Google Scholar · View at Scopus
  59. S. Petta, F. Macaluso, and A. Craxi, “Cardiovascular diseases and HCV infection: a simple association or more ?” Gut, vol. 63, no. 3, pp. 369–375, 2013. View at Publisher · View at Google Scholar
  60. M. Lee, H. Yang, S. Lu et al., “Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study,” The Journal of Infectious Diseases, vol. 206, no. 4, pp. 469–477, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Liao, T. Su, F. Sung, W. Chou, and T. Chen, “Does hepatitis C virus infection increase risk for stroke? A population-based cohort study,” PLoS ONE, vol. 7, no. 2, Article ID e31527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Lee, H. Yang, C. Wang et al., “Hepatitis C virus infection and increased risk of cerebrovascular disease,” Stroke, vol. 41, no. 12, pp. 2894–2900, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Hsu, J. Lin, H. Ho et al., “Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients,” Hepatology, vol. 59, no. 4, pp. 1293–1302, 2014. View at Publisher · View at Google Scholar
  64. A. A. Butt, W. Xiaoqiang, M. Budoff, D. Leaf, L. H. Kuller, and A. C. Justice, “Hepatitis C virus infection and the risk of coronary disease,” Clinical Infectious Diseases, vol. 49, no. 2, pp. 225–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. C.-S. Hsu, J.-H. Kao, Y.-C. Chao et al., “Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan,” Alimentary Pharmacology & Therapeutics, vol. 38, no. 4, pp. 415–423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. A. M. Guiltinan, Z. Kaidarova, B. Custer et al., “Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors,” American Journal of Epidemiology, vol. 167, no. 6, pp. 743–750, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. K. A. Forde, K. Haynes, A. B. Troxel et al., “Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study,” Journal of Viral Hepatitis, vol. 19, no. 4, pp. 271–277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Ishizaka, N. Ishizaka, E. Takahashi et al., “Association between hepatitis C virus core protein and carotid atherosclerosis,” Circulation Journal, vol. 67, no. 1, pp. 26–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. L. E. Adinolfi, L. Restivo, R. Zampino et al., “Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis,” Atherosclerosis, vol. 221, no. 2, pp. 496–502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Petta, D. Torres, G. Fazio et al., “Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations,” Hepatology, vol. 55, no. 5, pp. 1317–1323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Mostafa, M. K. Mohamed, M. Saeed et al., “Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors,” Gut, vol. 59, no. 8, pp. 1135–1140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Vassalle, S. Masini, F. Bianchi, and G. C. Zucchelli, “Evidence for association between hepatitis C virus seropositivity and coronary artery disease,” Heart, vol. 90, no. 5, pp. 565–566, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. O. Alyan, F. Kacmaz, O. Ozdemir et al., “Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified reardon severity score system,” Circulation Journal, vol. 72, no. 12, pp. 1960–1965, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. Z. M. Younossi, M. Stepanova, F. Nader, and E. Elsheikh, “Associations of chronic hepatitis C with metabolic and cardiac outcomes,” Alimentary Pharmacology and Therapeutics, vol. 37, no. 6, pp. 647–652, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Maruyama, M. Koda, N. Oyake et al., “Myocardial injury in patients with chronic hepatitis C infection,” Journal of Hepatology, vol. 58, no. 1, pp. 11–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. F. Bilora, E. Campagnolo, R. Rinaldi, A. Rossato, M. Arzenton, and F. Petrobelli, “Carotid and femoral atherosclerosis in chronic hepatitis C: a 5-year follow-up,” Angiology, vol. 59, no. 6, pp. 717–720, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Masia, S. Padilla, C. Robledano, J. M. Ramos, and F. Gutierrez, “Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients. A cross-sectional study,” BMC Infectious Diseases, vol. 11, article 265, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. C. M. Arcari, K. E. Nelson, D. M. Netski, F. J. Nieto, and C. A. Gaydos, “No association between hepatitis C virus seropositivity and acute myocardial infarction,” Clinical Infectious Diseases, vol. 43, no. 6, pp. e53–e56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Völzke, C. Schwahn, B. Wolff et al., “Hepatitis B and C virus infection and the risk of atherosclerosis in a general population,” Atherosclerosis, vol. 174, no. 1, pp. 99–103, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Shaheen, D. Echeverry, M. G. Oblad, M. I. Montoya, S. Teklehaimanot, and A. J. Akhtar, “Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III],” Diabetes Research and Clinical Practice, vol. 75, no. 3, pp. 320–326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Wang, S. Wang, W. Yao, T. Chang, and P. Chou, “Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study,” American Journal of Epidemiology, vol. 166, no. 2, pp. 196–203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Bugianesi, F. Salamone, and F. Negro, “The interaction of metabolic factors with HCV infection: does it matter?” Journal of Hepatology, vol. 56, supplement 1, pp. S56–S65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Pansuria, H. Xi, L. Li, X. Yang, and H. Wang, “Insulin resistance, metabolic stress, and atherosclerosis,” Frontiers in Bioscience, vol. 4, pp. 916–931, 2012. View at Google Scholar · View at Scopus
  84. G. Pasterkamp, “Methods of accelerated atherosclerosis in diabetic patients,” Heart, vol. 99, no. 10, pp. 743–749, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Boddi, R. Abbate, B. Chellini et al., “Hepatitis C virus RNA localization in human carotid plaques,” Journal of Clinical Virology, vol. 47, no. 1, pp. 72–75, 2010. View at Publisher · View at Google Scholar · View at Scopus